201 related articles for article (PubMed ID: 18844497)
1. Serum interleukin 6 (IL-6) and C-reactive protein (CRP) levels in colorectal adenoma and cancer patients.
Groblewska M; Mroczko B; Wereszczyńska-Siemiatkowska U; Kedra B; Lukaszewicz M; Baniukiewicz A; Szmitkowski M
Clin Chem Lab Med; 2008; 46(10):1423-8. PubMed ID: 18844497
[TBL] [Abstract][Full Text] [Related]
2. Markers of systemic inflammation and colorectal adenoma risk: Meta-analysis of observational studies.
Godos J; Biondi A; Galvano F; Basile F; Sciacca S; Giovannucci EL; Grosso G
World J Gastroenterol; 2017 Mar; 23(10):1909-1919. PubMed ID: 28348498
[TBL] [Abstract][Full Text] [Related]
3. Plasma Inflammatory Markers and Risk of Advanced Colorectal Adenoma in Women.
Song M; Mehta RS; Wu K; Fuchs CS; Ogino S; Giovannucci EL; Chan AT
Cancer Prev Res (Phila); 2016 Jan; 9(1):27-34. PubMed ID: 26511487
[TBL] [Abstract][Full Text] [Related]
4. [Clinical value of preoperative serum VEGF, CRP and IL-6 levels in colorectal carcinoma].
Li ZP; Han JQ; Meng XW; Yang YF
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):795-9. PubMed ID: 21163075
[TBL] [Abstract][Full Text] [Related]
5. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
6. Progressive increase of matrix metalloprotease-9 and interleukin-8 serum levels during carcinogenic process in human colorectal tract.
Biasi F; Guina T; Maina M; Nano M; Falcone A; Aroasio E; Saracco GM; Papotti M; Leonarduzzi G; Poli G
PLoS One; 2012; 7(7):e41839. PubMed ID: 22848630
[TBL] [Abstract][Full Text] [Related]
7. [Proinflammatory markers serum concentrations in patients with adenomatous colon polyps].
Oset P; Talar-Wojnarowska R; Kumor A; Małecka-Panas E
Przegl Lek; 2014; 71(2):78-81. PubMed ID: 25016780
[TBL] [Abstract][Full Text] [Related]
8. Serum CCL20 combined with IL-17A as early diagnostic and prognostic biomarkers for human colorectal cancer.
Wang D; Yuan W; Wang Y; Wu Q; Yang L; Li F; Chen X; Zhang Z; Yu W; Maimela NR; Cao L; Wang D; Wang J; Sun Z; Liu J; Zhang Y
J Transl Med; 2019 Aug; 17(1):253. PubMed ID: 31387598
[TBL] [Abstract][Full Text] [Related]
9. The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients.
Mroczko B; Groblewska M; Wereszczynska-Siemiatkowska U; Kedra B; Konopko M; Szmitkowski M
Clin Chim Acta; 2006 Sep; 371(1-2):143-7. PubMed ID: 16603145
[TBL] [Abstract][Full Text] [Related]
10. Relationship between soluble P-selectin and inflammatory factors (interleukin-6 and C-reactive protein) in colorectal cancer.
Dymicka-Piekarska V; Matowicka-Karna J; Gryko M; Kemona-Chetnik I; Kemona H
Thromb Res; 2007; 120(4):585-90. PubMed ID: 17169411
[TBL] [Abstract][Full Text] [Related]
11. Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.
Fahmueller YN; Nagel D; Hoffmann RT; Tatsch K; Jakobs T; Stieber P; Holdenrieder S
Int J Cancer; 2013 May; 132(10):2349-58. PubMed ID: 23047645
[TBL] [Abstract][Full Text] [Related]
12. Serum C-reactive protein correlates with survival in colorectal cancer patients but is not an independent prognostic indicator.
Chung YC; Chang YF
Eur J Gastroenterol Hepatol; 2003 Apr; 15(4):369-73. PubMed ID: 12655256
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of serum IL-23 in colorectal cancer.
Elessawi DF; Alkady MM; Ibrahim IM
Arab J Gastroenterol; 2019 Jun; 20(2):65-68. PubMed ID: 31155425
[TBL] [Abstract][Full Text] [Related]
14. Serum hepatocyte growth factor as a prognostic marker for stage II or III colorectal cancer patients.
Toiyama Y; Miki C; Inoue Y; Okugawa Y; Tanaka K; Kusunoki M
Int J Cancer; 2009 Oct; 125(7):1657-62. PubMed ID: 19569242
[TBL] [Abstract][Full Text] [Related]
15. Significance of inflammatory cytokines in the progression of colorectal cancer.
Chung YC; Chang YF
Hepatogastroenterology; 2003; 50(54):1910-3. PubMed ID: 14696431
[TBL] [Abstract][Full Text] [Related]
16. Circulating levels of C-reactive protein, interleukin-6 and tumor necrosis factor-α and risk of colorectal adenomas: a meta-analysis.
Zhang X; Liu S; Zhou Y
Oncotarget; 2016 Sep; 7(39):64371-64379. PubMed ID: 27608842
[TBL] [Abstract][Full Text] [Related]
17. Significance of Markers of Systemic Inflammation for Predicting Survival and Chemotherapeutic Outcomes and Monitoring Tumor Progression in Patients with Unresectable Metastatic Colorectal Cancer.
Shibutani M; Maeda K; Nagahara H; Ohtani H; Sakurai K; Yamazoe A; Kimura K; Toyokawa T; Amano R; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
Anticancer Res; 2015 Sep; 35(9):5037-46. PubMed ID: 26254405
[TBL] [Abstract][Full Text] [Related]
18. Pretreatment serum levels of hematopoietic cytokines in patients with colorectal adenomas and cancer.
Mroczko B; Szmitkowski M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B
Int J Colorectal Dis; 2007 Jan; 22(1):33-8. PubMed ID: 16520929
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic usefulness of serum interleukin 6 (IL-6) and C-reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis.
Mroczko B; Groblewska M; Gryko M; Kedra B; Szmitkowski M
J Clin Lab Anal; 2010; 24(4):256-61. PubMed ID: 20626020
[TBL] [Abstract][Full Text] [Related]
20. Soluble E-cadherin as a serum biomarker candidate: elevated levels in patients with late-stage colorectal carcinoma and FAP.
Weiss JV; Klein-Scory S; Kübler S; Reinacher-Schick A; Stricker I; Schmiegel W; Schwarte-Waldhoff I
Int J Cancer; 2011 Mar; 128(6):1384-92. PubMed ID: 20473926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
